-- World-class science companies combining resources and expertise to  
commercialize therapeutic cannabinoid pharmaceutical products to global market 

In a move destined to shape the global growth and evolution of the medicinal 
cannabinoid industry, medicinal cannabis horticultural company Bioarc Ltd. is 
joining forces with specialty drug development and manufacturing company Sante 
Laboratories to develop a portfolio of highly bioavailable whole plant 
therapeutic products. 

Logo - https://mma.prnewswire.com/media/1220204/Sante_Laboratories_Logo.jpg 

Clinicians are increasingly aware of the therapeutic potential of CBD and THC. 
While there are several cited sources to suggest over 110 known potentially 
active therapeutic compounds in cannabis, the pharmaceutical industry has been 
hindered by its inability to gain access to a wide range of medicinal cannabis 
genetics to extract and research the therapeutic potential for 
commercialization. 

That scenario changes with this agreement, which combines the best and most 
innovative research, development and drug delivery technology with the best 
starting materials to drive new markets. 

Best seeds + best technology = efficacious IP-protected cannabinoid 
formulations Bioarc has the world's most important legal collections of 
heritage medicinal cannabis seeds, with more than 1,000 accessions. The 
collection, established by David Watson and HortaPharm in the 1980s under 
license, contains a wide range of unique and agronomically valuable medicinal 
Cannabis varieties. 

Sante Laboratories, focused on building scalable and robust drug delivery and 
analytical solutions, will work with Bioarc to bring relevant know-how in 
cannabinoid sciences and drug development expertise infrastructure to the 
industry with its world-class, efficacious technology in drug development, 
pharmaceutical sciences and analytical chemistry. Sante Laboratories' 
achievements include the development of a lipid-based nanoparticle technology, 
Powered by Sante, to address solubility and bioavailability challenges 
associated with drugs like cannabinoids, rendering them more room-temperature 
stable and functional. 

This partnership aspires to develop a portfolio of cannabinoid formulations and 
evaluate safety and efficacy in a variety of preclinical models to support 
rapid entry into investigational first-in-man clinical studies. 

"It is exciting to partner with Bioarc, a leading global medicinal cannabis 
supplier to further define and optimize the therapeutic benefits of this 
plant," comments Sante Laboratories Chairman & Co-Founder Andrew Garnock. 
"Sante Laboratories is committed to addressing formulation challenges that the 
entire industry has struggled to overcome, using our proprietary drug delivery 
technology. We are aligned with the remarkable potential of cannabinoid 
therapeutics and equipped with solutions to move the industry forward. We are a 
drug delivery technology company, with the ultimate delivery system, and ready 
to partner, with strategics, to get products on the shelf." 

Bioarc Founder and Executive Chairman Michael Boyd adds, "We look forward to 
working with Sante Laboratories. Bioarc has the breeding technology to develop 
unique and very specific cultivars with consistent and identifiable traits – 
giving us precise pharmaceutical and agronomic profiles. 

"Our approach to our own branded product will be singular in its understanding 
of whole plant therapeutics. And will also focus on the best possible 
environments and cultivation processes in actually growing those plants. 

Sante Laboratories has the fit-for-purpose formulation technology to enable us 
to develop and test unique IP-protected cultivars. This agreement brings our 
industry to the cusp of tremendous growth." 

For additional information, visit www.SanteLabs.com and www.Bioarc.com.au. 

Media Note: For additional information and to schedule an interview, contact 
Media Relations Agency at 952-697-5220. 

About Santeì Laboratories 
Santeì Laboratories is a specialty drug development and manufacturing 
organization focused on innovating pharmaceutical and mainstream nutraceutical 
products using their proprietary advanced drug delivery solution from 
formulation to commercialization. Powered by Santeì(R) utilizes lipid 
encapsulation to get ingredients to the small intestine for proven optimal 
absorption with long-term room temperature stability. Supporting Santeì's 
custom product development and manufacturing services is their cGMP facility 
and ISO/IEC 17025:2017 accredited testing lab which provides exceptional 
science and regulatory expertise to their product development customers. 

About Bioarc 
Bioarc is a medicinal cannabis company focused on cultivar development for 
improved agronomics and therapeutic qualities. It brings together a team with 
global ambitions, rich with expertise in Plant Breeding, Horticulture, 
Pharmacy, Healthcare, Production, Distribution and Education. Bioarc's 
objective is to bring the best possible outcomes from sowing seed to providing 
for patients. 

Biography: Andrew Garnock, Santeì Laboratories Chairman & Co-Founder With more 
than twenty years of experience in the financial industry, Andrew Garnock is a 
Founding Partner and Chairman at Disruption Labs. He co-founded a private hedge 
fund which managed a derivative trading portfolio of over $500 million.

Over the past few years, Andrew has been at the forefront of the cannabinoid 
industry, and through his work over many years and with multiple projects 
Andrew adds a tremendous amount of knowledge and private investment experience 
within this space. Andrew's investment resume boasts a broad array of companies 
from technology, consumer discretionary, health and medicine, real estate, 
mining and more. 

Biography: Michael Boyd, Bioarc Founder & Executive Chairman 
Michael Boyd is the Chairman of Bioarc and has been involved since its 
inception. He has led the corporate structuring of the company and the 
development of its strategic vision. He has been involved in the creation of 
new enterprises, both in the private and public sectors, for over 25 years. 

Originally trained as a chartered accountant, he was a founding Director and 
Chairman of Sonic Healthcare Ltd, now an ASX-listed top 50 company. After 
leaving Sonic he started Foundation Healthcare, growing it to over 800 
healthcare professionals before it was acquired by Sonic. Michael is also 
Chairman of Jayex Healthcare Ltd an ASX-listed health technology company with 
operations in the United Kingdom, Australia and New Zealand.

CONTACT: +1 (952) 697-5214 
miked@publicity.com
 
SOURCE  Sante Laboratories